Clinical Trial

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-28; most recent amendment 2024-06-23.
Trial Details
NCT Number NCT05187338
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer +3 more
Enrollment 100 participants
Start Date 2021-11-01
Primary Completion 2029-10-30 (estimated)
Study Completion 2035-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-25